OBI.L LSE
Ondine Biomedical Inc.
1W: -9.3%
1M: -17.0%
3M: -36.7%
YTD: +5.4%
1Y: -40.9%
3Y: -33.9%
£9.75 ($0.13)
+0.00 (+0.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$2M
+70.3% ▲
5Y CAGR: +34.6%
Gross Profit
$1M
+87.9% ▲
5Y CAGR: +57.6%
Operating Income
-$19M
-31.3% ▼
Net Income
-$19M
-32.5% ▼
EPS (Diluted)
$-0.07
+4.2% ▲
EBITDA
-$18M
-34.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2M | $3M | $638K | $1M | $2M |
| YoY Growth | +286.0% | +43.4% | -75.2% | +88.6% | +70.3% |
| Cost of Revenue | $1M | $1M | $351K | $500K | $728K |
| Gross Profit | $649K | $1M | $287K | $703K | $1M |
| Gross Margin | 36.2% | 48.8% | 45.0% | 58.4% | 64.5% |
| R&D Expenses | $3M | $5M | $6M | $5M | $9M |
| SG&A Expenses | $12M | $13M | $12M | $10M | $11M |
| Operating Expenses | $17M | $19M | $19M | $16M | $21M |
| Operating Income | -$16M | -$18M | -$19M | -$15M | -$19M |
| Operating Margin | -886.2% | -682.0% | -2940.9% | -1230.7% | -949.0% |
| Interest Expense | $491K | $1M | $30K | $38K | $47K |
| Income Before Tax | -$16M | -$50M | -$19M | -$14M | -$19M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16M | -$50M | -$19M | -$14M | -$19M |
| Net Margin | -908.5% | -1949.6% | -3036.4% | -1198.0% | -932.1% |
| EPS (Diluted) | $-0.08 | $-0.26 | $-0.10 | $-0.07 | $-0.07 |
| EBITDA | -$15M | -$48M | -$19M | -$14M | -$18M |
| Shares Outstanding | 195M | 195M | 195M | 197M | 275M |